New Pfizer/BioNTech COVID-19 Vaccine Data Confirm Prior Results, Show T-Cell Boost

Jul 21 2020

• By Mandy Jackson

Listen to this article

While data from small trials are difficult to compare, it appears that T-cell responses to BNT162b1 may be stronger than those reported so far for Moderna’s competing mRNA-based vaccine.

Vaccination against the new Corona Virus SARS-CoV-2: A syringe being drawn up with SARS-CoV-2 vaccination. — Pfizer and BioNTech report results from a second Phase I/II study, which was conducted in Germany • Source: Shutterstock

Pfizer Inc. and BioNTech SE released Phase I/II results for their messenger RNA (mRNA)-based COVID-19 vaccine candidate BNT162b1, from a clinical trial conducted in Germany, that showed T-cell responses that may be stronger than those observed with a competing mRNA vaccine from Moderna, Inc. The data are also consistent with neutralizing antibody data reported previously from a US study.

Pfizer and BioNTech reported results on 20 July from 60 German trial participants, including 12 patients each injected with 1mcg,...

More from COVID-19

New COVID-19 Vaccines Shipping Soon, After Rapid Pivot To Address New Strain
Aug 22 2024
• By Alaric DeArment
Pfizer/BioNTech and Moderna rapidly adapted Comirnaty and Spikevax for the 2024-2025 season to address the KP.2 variant after the US FDA had advised them to target JN.1 in June.
Pfizer/BioNTech Combo Vaccine Shows Partial Flu Efficacy
Aug 16 2024
• By Alaric DeArment
The companies said their combination mRNA vaccine showed protection against SARS-CoV-2 and influenza A, but not influenza B.
AstraZeneca Moves To Join Invyvid In COVID-19 Prevention
Jul 04 2024
• By Elizabeth Cairns
The UK giant’s COVID-19 prophylactic sipavibart could soon reach Europe and competition is sparse.
Stock Watch: Thoroughly Moderna Missteps
Jun 18 2024
• By Andy Smith
When life hands a biotech company the equivalent of good grapes, the expectations are for its products to be the equivalent of fine wine. Before that Moderna looks likely to make lemonade.

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance
Jul 15 2026
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone
Jun 18 2026
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Finance Watch: Biopharma IPOs On The Upswing, Including Ex-US Offerings
Jun 17 2026
ghghghghghjhjhjhj